WuXi News

Filter By


WuXi STA’s New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection

SHANGHAI, March 27, 2019 – STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP inspection by the European Medical Products Agency (MPA). The new facility was opened at the end of 2018, and the successful inspection demonstrates the outstanding quality control system and rapid development of WuXi STA’s drug product services.

Read more


WuXi AppTec Reports Strong 2018 Annual Results

(SHANGHAI, March 22, 2019) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its audited annual results for the year ended December 31, 2018 today.

Read more


WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results

Shanghai, March 11, 2019 – Three of WuXi AppTec Laboratory Testing Division’s facilities, Drug Safety Testing, Bioanalytical Services and Medical Device Testing, recently completed regulatory inspections from the US FDA (Food and Drug Administration), OECD (Organization for Economic Co-operation and Development), and CNAS (China National Accreditation Service for Conformity Assessment), all with excellent results.

Read more


The First WuXi Healthcare Forum opens in Shanghai

Shanghai March 5, 2019 - The first “WuXi Healthcare Forum” opened at the St. Regis Shanghai Jing’an today, gathering together world-class scientists, alongside innovators, entrepreneurs, and investors. The forum attracts application of more than 5,000 industry leaders from 2,000 enterprises and organizations, spanning 20 countries, bring their collective insights to bare on the global challenges facing healthcare – exploring what breakthroughs have been achieved, the present realities and future possibilities.

Read more


WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery

SHANGHAI and SAN DIEGO, February 19, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec – and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing collaboration for sublingual delivery.

Read more